EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
What Is Cognizant Technology Solutions (CTSH) Signaling With Its Latest AI Push?
Gilead Sciences' (GILD) Overweight Rating Reaffirmed at Cantor Fitzgerald - Stock Observer
Gilead Sciences (NASDAQ:GILD) Given Overweight Rating at Cantor Fitzgerald - Stock Observer
Cantor Fitzgerald Reaffirms Overweight Rating for Gilead Sciences (NASDAQ:GILD) - Stock Observer
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - Daily Political
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Truist Financial Analyst Says
Gilead Sciences (NASDAQ:GILD) Stock Gets Price Target Boost from JPMorgan Chase & Co.
GILD Maintained by Morgan Stanley -- Price Target Lowered to $16
Morgan Stanley Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $163.00
Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)
Gilead Sciences (NASDAQ:GILD) Stock Price Target Cut by Morgan Stanley - Stock Observer
Nurix Extends Gilead Oncology Research Collaboration For Two Years
Zacks Research Lowers Earnings Estimates for Gilead Sciences
Gilead (NASDAQ: GILD) CEO sells 15,000 shares under a preset plan - Zolmax
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Now Rated "Moderate Buy" by Wall Street Brokerages
31,384 Gilead Sciences, Inc. $GILD Shares Sold by CX Institutional
Biotech Stocks To Watch Now - October 2nd - Daily Political
Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock
Biotech Stocks To Watch Now - October 2nd - Zolmax
Gilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O'day Sells 15,000 Shares - Daily Political
Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD
HIV prevention drug hailed as breakthrough, but who gets access?
Gilead Sciences (NASDAQ:GILD) Stock Rating Cut to "Hold" at Zacks Research
Zacks Research Downgrades Gilead Sciences (NASDAQ:GILD) to Hold - Stock Observer
GILD: HIV Growth Still Leads, Oncology And Immunology Now Carry More Weight
Vascular Dementia Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2034 - DelveInsight | Pfizer, Gilead Sciences, ViiV Healthcare | ABNewswire
Best Medical Stocks To Watch Today - September 29th - Markets Daily
Best Pharmaceutical Stocks To Follow Now - September 26th - Daily Political
Can Lenacapavir Power Gilead Sciences (GILD)'s Next Growth Phase?
Promising Pharmaceutical Stocks To Research - September 28th - Zolmax
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?
Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?
Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?
A human single-cell atlas identifies OLR1 + scar-associated macrophages as a potential therapeutic target for chronic liver disease
Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?
Gilead's HIV Concentration or Pfizer's Patent Cliff: Which Risk is Easier to Own?
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts
Reviewing Gilead Sciences (NASDAQ:GILD) & Protalix BioTherapeutics (NYSE:PLX) - Stock Observer
Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc.
FY2026 EPS Estimate for Gilead Sciences Boosted by Analyst - Daily Political
Biotech Stocks To Follow Now - September 23rd - Stock Observer
Medical Stocks To Watch Today - September 22nd - Stock Observer
FY2027 EPS Forecast for Gilead Sciences Boosted by Analyst - Daily Political
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
State Street Corp Raises Position in Gilead Sciences, Inc. $GILD
Gilead Sciences FY2026 EPS Increased by Erste Group Bank
Biotech Stocks To Consider - September 19th - Zolmax
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Drugmakers move closer to launch landmark HIV drug as CDSCO eases approval process
Biotech Stocks To Watch Now - September 21st - Daily Political
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig
GILD: HIV Prevention Promise Faces A Harder Test, Growth Still Looks Thin
Erste Group Bank Estimates Gilead Sciences FY2027 Earnings
Why Morgan Stanley likes Gilead's HIV prevention play
Gilead Sciences (NASDAQ:GILD) Rating Increased to Buy at Wall Street Zen
Gilead Sciences (NASDAQ:GILD) Upgraded to Buy at Wall Street Zen
Insider Selling: Gilead Sciences (NASDAQ:GILD) CFO Sells $435,870.00 in Stock - Daily Political
Gilead Strengthens HIV Growth Platform with Expanded Latin America Access
Top Medical Stocks To Watch Today - September 18th - Daily Political
Nykredit A S Invests $140.59 Million in Gilead Sciences, Inc. $GILD
Top Medical Stocks To Keep An Eye On - September 17th - Stock Observer
Dr Reddy's inks licensing deal with Gilead for once-yearly HIV lenacapavir
Biotech Stocks To Keep An Eye On - September 17th - Stock Observer
Dr Reddy's Labs Secures License for Gilead's Revolutionary Once-Yearly HIV Prevention Drug, ETPharma
Dr. Reddy's expands Gilead pact for HIV prevention drug
Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock
Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells $432,660.00 in Stock
Johanna Mercier Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - Stock Observer
Gilead Partners with PAHO to Expand Access to HIV Prevention Drug in Latin America and Caribbean, ETPharma
Medical Stocks To Consider - September 15th - Zolmax
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances - Stock Observer
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Gilead Sciences Target of Unusually High Options Trading (NASDAQ:GILD) - Daily Political
Gilead Sciences, Inc. (GILD) To Go Ex-Dividend on September 15th
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC
The Manufacturers Life Insurance Company Sells 148,344 Shares of Gilead Sciences, Inc. $GILD
Bullseye Investment Management LLC Takes Position in Gilead Sciences, Inc. $GILD
Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales
16,506 Shares in Gilead Sciences, Inc. $GILD Bought by Bullseye Investment Management LLC - Stock Observer
Best Medical Stocks To Research - September 11th - Daily Political
Baird Financial Group Inc. Grows Holdings in Gilead Sciences, Inc. $GILD
RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth
Tidal Investments LLC Raises Position in Gilead Sciences, Inc. $GILD
Gilead Sciences, Inc. $GILD Shares Acquired by National Pension Service
Gilead News
GE Vernova Stock Forecast & Analysis: Will Data-Centre Power and Grid Investment Fuel the Next Rally?
Samsung Electronics Stock Price Forecast 2026–2027: Can Record Q3 Profit Extend the AI Rally?
GBP/USD Forecast: Can Sterling Hold 1.32 as Fed Rate-Hike Bets Rise?
Advanced CFD Trading Tools Review: Which Tools Can Improve Your Trading Decisions?
Gold Price Trend 2024-2026: From $2,000 to Record Highs, What Comes Next?
Latest news
Show more
Delta Earnings Preview: Can Strong Travel Demand Offset Oil Above $104?
Oil Prices Surge as Brent Tops $104 on Iran Tensions and Hurricane Isaias
US Consumer Sentiment Preview: Will Rising Inflation Expectations Keep the Fed Hawkish?
Tesla Stock Slips Despite $500 Price Target as FSD Delays and Spending Stay in Focus
EUR/USD Holds Near a 17-Month Low as France’s Debt Crisis Weighs on the Euro
AI Stocks Tumble as OpenAI Revenue Run Rate Comes In $20 Billion Below Earlier Reports
